Rezq Bio is developing therapies designed to restore immune tolerance, beginning with type 1 diabetes. Its lead program uses a patient’s own dendritic cells to address the immune response that attacks healthy tissue. The company is preparing this investigational therapy for Phase 1b/2a development and exploring microsphere-based delivery for broader applications. [1]
The Pittsburgh company’s scientific foundation includes University of Pittsburgh diabetes research and co-founder David Finegold’s clinical expertise. Its pipeline also explores localized treatment for inflammatory bowel disease and protection of transplanted cells, with the goal of reducing reliance on broad immune suppression. [2] [1]